Holen Sie sich die Stockscreener-App
1.02
3.03%
0.03
Handel nachbörslich:
1.00
-0.02
-1.96%
Schlusskurs vom Vortag:
$0.99
Offen:
$0.99
24-Stunden-Volumen:
585.81K
Relative Volume:
0.62
Marktkapitalisierung:
$91.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.4834
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
+2.76%
1M Leistung:
-0.97%
6M Leistung:
-27.14%
1J Leistung:
-15.70%
1-Tages-Spanne:
$0.951
$1.02
1-Wochen-Bereich:
$0.925
$1.05
52-Wochen-Spanne:
$0.923
$2.11
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.02 | 91.88M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
HB Wealth Management LLC Acquires New Shares in Immunic, Inc. (NASDAQ:IMUX) - Defense World
IMUX Stock Touches 52-Week Low at $0.97 Amid Market Challenges - MSN
Immunic, Inc. (NASDAQ:IMUX) Sees Large Increase in Short Interest - MarketBeat
Jane Street Group LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $12.67 - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - MarketBeat
Immunic eyes transformative year ahead for MS therapy vidofludimus calciumICYMI - Proactive Investors Australia
Immunic ‘on track’ with MS clinical trials testing vidofludimus calcium - Multiple Sclerosis News Today
Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital - Defense World
Immunic COO Jason Tardio discusses key 2024 highlights, 2025 milestones - Proactive Investors Australia
Immunic eyes key data readout from multiple sclerosis trial in 2025 - Proactive Investors Australia
D. Boral Capital Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PR Newswire
State Street Corp Boosts Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.80 - Defense World
Immunic CEO Daniel Vitt secures new employment terms - Investing.com
Immunic CEO Daniel Vitt secures new employment terms By Investing.com - Investing.com South Africa
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - Defense World
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 10.3% in November - MarketBeat
Immunic CEO Dr Daniel Vitt on successful 2024, with more to come in the year ahead - Proactive Investors Australia
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - The Eastern Progress Online
Janus Henderson Group PLC Sells 1,974,566 Shares of Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic CSO discusses breaking the IBD stigma to mark Crohn's and Colitis Awareness Week - Proactive Investors UK
Broad Benefits Of Immunic MS Drug Could Transform Treatment - News & Insights
B. Riley Has Bearish Forecast for Immunic FY2024 Earnings - Defense World
B. Riley Estimates Immunic's FY2024 Earnings (NASDAQ:IMUX) - MarketBeat
FY2024 Earnings Estimate for Immunic Issued By HC Wainwright - Defense World
IMUXImmunic, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on Immunic (NASDAQ:IMUX) - Defense World
HC Wainwright Estimates Immunic’s Q4 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. to Participate in Investor Conference in December - The Malaysian Reserve
Immunic to present at Piper Sandler 36th Annual Healthcare Conference - Proactive Investors USA
What is HC Wainwright's Estimate for Immunic Q4 Earnings? - MarketBeat
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook - Investing.com Nigeria
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook By Investing.com - Investing.com South Africa
Immunic initiated with a Buy at H.C. Wainwright - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Average Price Target from Analysts - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.7% in October - Defense World
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):